Evaluation of correlations of Plasma Levels of Oxytocin, Omentin-1 and Irisin in Diabetic and Non-Diabetic Metabolic Syndrome Patients: A Cross Sectional Study in Jordan

Rama Kahwaji, Violet Kasabri, Nailya Bulatova, Amal Akour, Haidar Bustanji, Nahla Khawaja, Dana Hyasat, Yasser Bustanji, Ayman Zayed, Munther Momani, Sundus Mashallah, Yusuf AlHiari, Mais Al-Nouaaimi


Metabolic syndrome (Mets) risk factor biomarkers, namely oxytocin (OXT), omentin-1 and irisin,
plasma levels were evaluated via colorimetric enzymatic bioassays. A total of 195 Mets patients were
recruited from the outpatients’ diabetes and endocrinology clinics at the National Center for Diabetes
Endocrinology and Genetics. Participants were subdivided according to their fasting glycemia status
into either the normoglycemic subjects group (Mets-controls) or dysglycemic subjects group (Metspre/
T2DM). Enrolled recruits in both study arms were BMI (body mass index)-, gender- and agematched.
Distinctively in the Mets-pre/T2DM group; mean circulating levels of both OXT (pg/mL) and omentin-1
(ng/mL) were significantly lower but mean irisin plasma levels (ng/mL) were substantially higher (p<0.01
vs. respective Mets-controls'). Markedly, in the total pool of Mets-participants, plasma OXT levels
correlated inversely with irisin plasma levels but proportionally with omentin-1 plasma levels; [Spearman
correlation coefficient r =-0.377(N=147) for irisin and r = 0.321(N=138) for omentin-1]. Meanwhile,
omentin-1 plasma levels correlated inversely (p<0.001) with irisin’s [r =-0.309(N=121)]. These findings
indicate that like OXT, irisin and omentin-1 can be postulated as surrogate biomarkers and/or putative
pharmacologic agents to limit the deleterious effect of chronic subclinical inflammatory process among
Mets individuals with glucose profile abnormalities compared to apparently healthy Mets ones.


Oxytocin, Metabolic Syndrome, Omentin-1, Irisin; Type 2 Diabetes Mellitus,

Full Text:



  • There are currently no refbacks.